Abstract
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of skeletal malformations and presents progressive extra-skeletal ossification. The 617G>A (R206H) mutation in the activin receptor type IA (ACVR1) gene has been identified in all examined individuals with FOP of various ethnic groups, including Caucasian and Chinese descents. Here, we examined three Japanese patients with FOP for ACVR1 mutations. We identified the 617G>A mutation in all three patients. Our results suggest that the mutation in the ACVR1 gene is common and recurrent in the global population.
Introduction
Fibrodysplasia ossificans progressiva (FOP; OMIM 135100) is a rare genetic disorder with autosomal dominant transmission (Kaplan et al. 2002). FOP is the most severe disorder of heterotopic ossification and results in the postnatal formation of an ectopic skeleton (Cohen et al. 1993; Kaplan et al. 1993, 2004). Heterotopic ossification in FOP begins in childhood and can be induced most often by trauma. The ossification is episodic and progressive, leading to extra-articular ankylosis of all major joints of the axial and appendicular skeleton (Cohen et al. 1993; Kaplan et al. 1993, 2004), rendering movement impossible. Congenital malformation of the great toes is common.
Recently, Shore et al. (2006) mapped FOP to chromosome 2q23-24 by linkage analysis and identified a heterozygous mutation (617G>A; R206H) in the glycine-serine (GS) activation domain of ACVR1, encoding a BMP type I receptor. They found the mutation in 39 families examined, including African–American, European–American, European (UK), Korean, and Native Brazilian descents. Furthermore, a Taiwanese patient with a de novo ACVR1 617G>A mutation has been reported (Lin et al. 2006). Only the 617G>A mutation has been found in FOP so far. To investigate whether ACVR1 617G>A mutation is common and recurrent, we examined the ACVR1 gene in Japanese FOP patients. We found the 617G>A mutation in all patients examined.
Materials and methods
The diagnosis of FOP was based on clinical and radiographic findings. The phenotypes of the three patients are summarized in Table 1. All patients were sporadic. Peripheral blood or fingernails were obtained with informed consent from the patients. Genomic DNA was extracted using standard procedures. We amplified exon 4 by polymerase chain reaction (PCR) using primer sequences 5′-CCAGTCCTTCTTCCTTCTTCC-3′ and 5′-AGCAGATTTTCCAAGTTCCATC-3′ (Shore et al. 2006). PCR products were sequenced directly using an ABI Prism 3700 automated sequencer (Applied Biosystems, Foster City, CA).
Results and discussion
Direct sequence analysis of genomic DNA demonstrated the presence of a single heterozygous 617G>A mutation in all three patients with FOP (Fig. 1). No other mutation was identified. Thus, we found that Japanese patients with FOP also had the same ACVR1 617G>A mutation. These results suggest that the mutation is common and recurrent in FOP, regardless of ethnic background. The presence of the mutation hot spot facilitates molecular diagnosis in clinical practice. Early diagnosis is very critical for FOP patients to avoid ossification-causing stimuli, including medical intervention.
Accumulation of mutation in a particular single nucleotide is most famous in achondroplasia, the most common skeletal dysplasia (OMIM 100800). Mutations in the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) are identified in achondroplasia, and more than 99% of the FGFR3 mutation occurs in a particular single nucleotide, 1138G (1138G>A/C (G380R) mutation). To date, this represents the most mutable single nucleotide reported in the human genome. In both achondroplasia and FOP, the mutations are CpG dinucleotide changes, and paternal age effects in sporadic cases have been reported (Penrose 1955; Tuente et al. 1967). In achondroplasia, the initial and subsequent studies (Shiang et al. 1994; Rousseau et al. 1994; Bellus et al. 1995) found only G380R mutation in more than 200 subjects, which led some researchers to conclude that achondroplasia is defined by recurrent G380R mutation (Bellus et al. 1995). However, the different mutation in FGFR3 has been found later in slightly atypical cases (Ikegawa et al. 1995; Superti-Furga et al. 1995). The mutation G375C is also in the transmembrane domain. The phenotypic difference between the common and uncommon mutation are subtle (Nishimura et al. 1995).
In contrast to homogeneity of the achondroplasia phenotype, the clinical manifestation of FOP is considerably diverse, which argues against the homogeneity of the FOP mutation. In a family reported by Shore et al. (2006) who showed ambiguous FOP feature, the ACVR1 617G>A mutation was not identified. More extensive search for the FOP/ACVR1 mutation that includes patients with atypical FOP phenotypes is necessary to conclude that the single mutation determines the FOP phenotype.
References
Bellus GA, Hefferon TW, Ortiz de Luna RI, Hecht JT, Horton WA, Machado M, Kaitila I, McIntosh I, Francomano CA (1995) Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 56(2):368–373
Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS (1993) The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 75(2):215–219
Ikegawa S, Fukushima Y, Isomura M, Takada F, Nakamura Y (1995) Mutations of the fibroblast growth factor receptor-3 gene in one familial and six sporadic cases of achondroplasia in Japanese patients. Hum Genet 96(3):309–311
Kaplan FS, McCluskey W, Hahn G, Tabas JA, Muenke M, Zasloff MA (1993) Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family. J Bone Joint Surg Am 75(8):1214–1220
Kaplan FS, Shore EM, Connor JM (2002) Fibrodysplasia ossificans progressiva (FOP). In: Royce PM, Steinmann B (eds) Connective tissue and its heritable disorders: molecular, genetic, and medical aspects, 2nd edn. Wiley-Liss, New York, pp 827–840
Kaplan FS, Glaser DL, Hebela N, Shore EM (2004) Heterotopic ossification. J Am Acad Orthop Surg 12(2):116–125
Lin GT, Chang HW, Liu CS, Huang PJ, Wang HC, Cheng YM (2006) De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva. J Hum Genet 51(12):1083–1086
Nishimura G, Fukushima Y, Ohashi H, Ikegawa S (1995) Atypical radiological findings in achondroplasia with uncommon mutation of the fibroblast growth factor receptor-3 (FGFR-3) gene (Gly to Cys transition at codon 375). Am J Med Genet 59(3):393–395
Penrose LS (1955) Parental age and mutation. Lancet 269(6885):312–313
Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371(6494):252–254
Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78(2):335–342
Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Brown MA, Kaplan FS (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38(5):525–527
Superti-Furga A, Eich G, Bucher HU, Wisser J, Giedion A, Gitzelmann R, Steinmann B (1995) A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr 154(3):215–219
Tuente W, Becker PE, Von Knorre GV (1967) Zur Genetik der Myositis ossificans progressiva. Humangenetik 4(4):320–351
Acknowledgments
We thank the patients and their relatives who co-operated in this study, and Ms. Tomoko Kusadokoro for her technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nakajima, M., Haga, N., Takikawa, K. et al. The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva. J Hum Genet 52, 473–475 (2007). https://doi.org/10.1007/s10038-007-0128-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10038-007-0128-3
Keywords
This article is cited by
-
The biological function of type I receptors of bone morphogenetic protein in bone
Bone Research (2016)
-
Phenotypic differences of patients with fibrodysplasia ossificans progressive due to p.Arg258Ser variants of ACVR1
Human Genome Variation (2015)
-
Fibrodysplasia ossificans progressiva
Medizinische Genetik (2012)
-
Deformity of the great toe in fibrodysplasia ossificans progressiva
Journal of Orthopaedic Science (2010)
-
Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva
Clinical Rheumatology (2010)